Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Update on treatment in acute stage of Kawasaki disease

가와사끼병 급성기 치료의 최신 지견

  • Han, Ji Whan (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
  • 한지환 (가톨릭대학교 의과대학 소아과학교실)
  • Received : 2008.03.22
  • Accepted : 2008.04.13
  • Published : 2008.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Kawasaki disease (KD) was first described by Dr. Tomisaku Kawasaki in his 1975 study, published in Pediatrics. Its pathogenesis is still not clearly understood. Early diagnosis and treatment are very important to preventing concomitant coronary artery complications. Most KD patients respond well to the standard treatment of aspirin and intravenous immunoglobulin; however, some of them are refractory to the standard treatment, and so adjuvant therapies with corticosteroids and anti-tumor necrosis $factor-{\alpha}$ ($TNF-{\alpha}$) antibody are necessary. In this article, the author reviews and summarizes the most recent literature on the treatment of refractory KD.

Keywords

References

  1. Kawasaki T, Kosaki F, Okawa S, Shig ernatsu I, Yanagawa H A new infantile acute febrile mucocutaneous lymph node syndrome (11LNS) prevailing in Japan, Pediatrics 197454: 271-6.
  2. Behan MW, Storey RF. Antip1ate1et therapy in cardiovascular disease, Postgrad Med J 2004;80: 155-164, https://doi.org/10.1136/pgmj.2003.007062
  3. Dajani AS, Taubert KA, Takahashi M, Bierman FZ, Freed 11D, Ferrieri P et al. Guidelines for long term management of patients with Kawasaki disease, Report from the Com¬mittee on Rheumatic Fever, Endocarditis, and Kawasaki disease, Council on Cardiovascular Disease in the Young, Americal Heart Association, Circulation 1994;89:916-22, https://doi.org/10.1161/01.CIR.89.2.916
  4. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose, J Pediatr 1997;131:888-93. https://doi.org/10.1016/S0022-3476(97)70038-6
  5. Behan MW, Storey RF. Antiplatelet therapy in cardiovascular disease, Postgrad Med J 2004;80: 155-64, https://doi.org/10.1136/pgmj.2003.007062
  6. FitzGerald GA. Dipyridamole. N Engl J Med 1987:316:1247-1257. https://doi.org/10.1056/NEJM198705143162005
  7. Patrono C, Coller B, Dalen JE, Fuster V, Gent M, Harker LA et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects, Chest 1998;114(5 Suppl):470S-88S. https://doi.org/10.1378/chest.114.5_Supplement.470S
  8. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999:100:1667-72. https://doi.org/10.1161/01.CIR.100.15.1667
  9. Behan MW, Storey RF. Antip1ate1et therapy in cardiovascular disease, Postgrad Med J 2004;80:155-164, https://doi.org/10.1136/pgmj.2003.007062
  10. O'Brien M, Parness lA, Neufeld EJ, Baker AL, Sunde1 RP, Newburger JW, Ticlopidine plus aspirin for coronary throm¬bosis in Kawasaki disease, Pediatrics 2000;105:E64, https://doi.org/10.1542/peds.105.5.e64
  11. Furusho K, Sato K, Soeda T, Matsumoto H, Okabe T, Hirota T et al. High-dose intravenous garnrnaglobulin for Kawasaki disease, Lancet 1983;2:1359,
  12. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE et al. The treatment of Kawasaki syndrome with intravenous gamma globulin, N Engl J Med 1986;315: 341-7. https://doi.org/10.1056/NEJM198608073150601
  13. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991:324:1633-9. https://doi.org/10.1056/NEJM199106063242305
  14. Terai M, Shulman ST. Prevalence of coronary artery abnor¬malities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose, J Pediatr 1997:131:888-93 https://doi.org/10.1016/S0022-3476(97)70038-6
  15. Melish ME. Kawasaki syndrome, Pediatr Rev 1996;17:153-62, https://doi.org/10.1542/pir.17-5-153
  16. Marasini M, Pongig lione G, Gazzolo D, Campelli A, Ribal¬done D, Caponnetto S, Late intravenous gamma globulin treatment in infants and children with Kawasaki disease and coronary artery abnormalities, Am J Cardiol 1991 68: 796-7. https://doi.org/10.1016/0002-9149(91)90658-8
  17. Han RK, Silverman ED, Newman A, McCrindle BW, Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Ka¬wasaki disease. Arch Pediatr Adolesc Med 2000;154:694-9. https://doi.org/10.1001/archpedi.154.7.694
  18. Wallace CA, French JW, Kahn SJ, Sherry DD, Initial intravenous garnrnaglobulin treatment failure in Kawasaki disease, Pediatrics 2000;105:E78, https://doi.org/10.1542/peds.105.6.e78
  19. Durongpisitkul K, Soong swang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C, Irnrnunoglobulin failure and retreatment in Kawasaki disease, Pediatr Cardiol 2003; 24:145-8. https://doi.org/10.1007/s00246-002-0216-2
  20. Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW, Gamma globulin retreatrnent in Kawasaki disease, J Pediatr 1993:123:657-9. https://doi.org/10.1016/S0022-3476(05)80972-2
  21. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glade 11P, Intravenous gamma-globulin treatment and retreatment in Kawasaki disease, US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998:17:1144-8. https://doi.org/10.1097/00006454-199812000-00009
  22. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement, Pediatrics 1979; 63:175-9.
  23. Wright DA, Newburger JW, Baker A, Sunde1 RP, Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids, J Pediatr 1996;128:146-9, https://doi.org/10.1016/S0022-3476(96)70447-X
  24. Sunde1 RP, Baker AL, Fulton DR, Newburger JW, Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial, J Pediatr 2003;142:611-6, https://doi.org/10.1067/mpd.2003.191
  25. Newburger JW, Treatment of Kawasaki disease: cortico-steroids revisited, J Pediatr 1999;135:411-3, https://doi.org/10.1016/S0022-3476(99)70160-5
  26. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Committee on Rheumatic Fever Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association, Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association, Pediatrics 2004;114:1708-33, https://doi.org/10.1542/peds.2004-2182
  27. Newburger IW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL et al. Pediatric Heart Network Inve¬stigators, Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease, N Engl J Med 2007;356:663-75. https://doi.org/10.1056/NEJMoa061235
  28. Furukawa S, Matsubara T, Umezawa Y, Motohashi T, Ino T, Yabuta K Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease, Eur J Pediatr 1994;153:663-7. https://doi.org/10.1007/BF02190688
  29. Wallace CA, French IW, Kahn SJ, Sherry DD, Initial intravenous gamma-globulin treatment failure in Kawasaki disease, Pediatrics 2000;105:E78, https://doi.org/10.1542/peds.105.6.e78
  30. Lee MS, An SY, jang GC, Kim DS, A case of intravenous immunoglobulin-resistant Kawasaki disease treated with methotrexate, Yonsei Med J 2002;43:527-32, https://doi.org/10.3349/ymj.2002.43.4.527
  31. Inarno Y, Okubo T, Wada M, Fuchig arni S, Hashimoto K, Fuchigarni T, et al. Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients, Three case reports, Int Arch Allergy Irnrmmol 2002;127:89-94. https://doi.org/10.1159/000048174
  32. Zaitsu M, Hamasaki Y, Tashiro K, Matsuo M, Ichirnaru T, Fujita I et al. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase¬type 2 in Kawasaki disease, J Infect Dis 2000;181:1101-9, https://doi.org/10.1086/315332
  33. Raman V, Kim J, Sharkey A, Chatila T. Response of refrac¬tory Kawasaki disease, Pediatr Infect Dis J 2001 20:635-37, https://doi.org/10.1097/00006454-200106000-00022
  34. Matsubara T, Furukawa S, Yabuta K Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary artery lesions, Clin Immunol Immunopathol 1990;56:29-36, https://doi.org/10.1016/0090-1229(90)90166-N
  35. Leung DY, Cotran RS, Kurt-Jones E, Burns JC, Newburg er IW, Pober JS, Endothelial activation in the pathogenesis of Kawasaki disease, Trans Assoc Am Physicians 1989;102: 131-8.
  36. Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-S, interieukin-S, and tumor necrosis factor alpha among patients with Kawasaki disease, J Pediatr 1992; 121:924-6. https://doi.org/10.1016/S0022-3476(05)80343-9
  37. Etheridge SP, Tani L Y, Minich LL, Revenaugh JR Platelet glycoprotein Ilb/Illa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease, Cathet Cardiovasc Diagn 1998;45:264-8, https://doi.org/10.1002/(SICI)1097-0304(199811)45:3<264::AID-CCD10>3.0.CO;2-2
  38. Weiss JE, Eberhard BA, Chowdhury D, Gottheb BS. Infliximab as a novel therapy for refractory Kawasaki disease, J Rheumatol 2004;31:808-10.
  39. Lahdenne P, Vhsalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopa¬thic arthritis: an open label study, Ann Rheum Dis 2003; 62:245-7. https://doi.org/10.1136/ard.62.3.245
  40. Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS, Infliximab (RE11ICADE) therapy in the treatment of pediatric Crohn'.s disease.Am J Gastroenterol 2003;98:833-8, https://doi.org/10.1111/j.1572-0241.2003.07343.x
  41. Burns JC, Mason WH, Hauger SB, janai H, Bastian IF, Wohrley JD et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7. https://doi.org/10.1016/j.jpeds.2004.12.022
  42. Riegert-johnson DL, Godfrey JA, Myers JL, Hubrnayr RD, Sandborn WJ, Loftus EV Jr. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion, Inflamm Bowel Dis 2002:8:186-91. https://doi.org/10.1097/00054725-200205000-00005
  43. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A et al. Influence of irnrmmogenicity on the long-term efficacy of infliximab in Crohn'.s disease, N Engl J Med 2003;348:601-8. https://doi.org/10.1056/NEJMoa020888
  44. Cohen RD, Tsang IF, Hanauer SB. Infliximab in Crohn'.s disease: first anniversary clinical experience, Am J Gastroenterol 2000;95:3469-77. https://doi.org/10.1111/j.1572-0241.2000.03363.x
  45. Crandall WV, Mackner LM, Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003;17:75-84,
  46. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha -neutralizing agent, N Engl J Med 2002;346:623-6. https://doi.org/10.1056/NEJM200202213460815
  47. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel IN, Wise RP, Brown SL, Udall JN Jr. Braun Mlvl. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70, https://doi.org/10.1002/art.10583
  48. Kroesen S, Widmer AF, Tyndall A, Hasler P, Serious bacterial infections in patients with rheurnatoid arthritis under anti-TNF-alpha therapy, Rheumatology 2003;42:617-21. https://doi.org/10.1093/rheumatology/keg263
  49. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun Mlvl. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration, Arthritis Rheum 2002;46: 3151-8. https://doi.org/10.1002/art.10679
  50. De Rycke L, Kruithof E, Van Darnrne N, Hoffman IE, Van den Bossche N, Van den Bosch F et al. Antinuclear antibodies following infliximab treatment in patients with rheurnatoid arthritis or spondylarthropathy. Arthritis Rheum 2003;48:1015-23. https://doi.org/10.1002/art.10876
  51. Armbrust W, Karnphuis SS, Wolfs TW, Fiselier TJ, Nikkels PG, Kuis W et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology 2004;43:527-9. https://doi.org/10.1093/rheumatology/keh074
  52. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD et al. Pediatric Rheumatology Collaborative Study Group, Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheurnatoid arthritis, Arthritis Rheum 200654:1987-94 https://doi.org/10.1002/art.21885
  53. Lahdenne P, Vhsalo P, Honkanen V, Infliximab or etanercept in the treatment of children with refractory juvenile idiopa¬thic arthritis: an open label study, Ann Rheum Dis 2003;62: 245-7. https://doi.org/10.1136/ard.62.3.245
  54. Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS, Infliximab (RE¬11ICADE) therapy in the treatment of pediatric Crohn' s disease, Am J Gastroenterol 2003;98:833-8, https://doi.org/10.1111/j.1572-0241.2003.07343.x
  55. Foster RH, Wiseman LR Abciximab. An updated review of its use in ischaemic heart disease, Drugs 1998;56:629-65 https://doi.org/10.2165/00003495-199856040-00014

Cited by

  1. Helicobacter pylori 감염 소아에서 유전형과 위점막 림프구 vol.12, pp.2, 2008, https://doi.org/10.5223/kjpgn.2009.12.2.140
  2. Clinical and Endoscopic Findings in Children with Peptic Ulcer in Terms of $Helicobacter$ $pylori$ in Incheon vol.15, pp.1, 2008, https://doi.org/10.5223/kjpgn.2012.15.1.23